-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Yimaitong compiles and organizes, please do not reprint without authorization.
Guide: Will radioactive iodine treatment of hyperthyroidism increase the risk of cancer? At the 2021 American Endocrine Society Annual Meeting (ENDO), Dr.
Cari Kitahara from the National Cancer Institute (affirmative) and Dr.
Brian Kim from Rush University Medical Center (affirmative) debated this topic.
Zhengfang Dr.
Cari Kitahara believes that ionizing radiation is a known carcinogen, which is related to the increased risk of solid cancer and blood cancer.
Dr.
Kitahara summarized a study published by his team in JAMA Intern Med in 2019 (PMID: 31380945), which investigated a group of patients with hyperthyroidism (18,805) who were treated with RAI, and the study was followed up for 70 years.
This study showed that patients with hyperthyroidism treated with RAI have an increased risk of all solid cancers (especially breast cancer in women), even if the patients received relatively low doses of RAI.
The opponent, Dr.
Brian Kim, believes that despite the extensive heterogeneity in previous studies, there have been more than 100 years of safety data regarding the correlation between RAI treatment and thyroid cancer.
Relevant recommendations based on these evidences can ensure the overall safety of RAI in patients with hyperthyroidism.
Although scholars failed to reach a consistent conclusion on the "relevance of radioactive iodine and cancer risk" in this debate, there are still important revelations: it is important to evaluate the quality of evidence in previous related studies, and recently published studies The data prompts us to conduct more related investigations.
Yimaitong compiled and compiled from: Angela M.
Leung.
Thyroid Highlights From ENDO 2021[EB/OL].
Guide: Will radioactive iodine treatment of hyperthyroidism increase the risk of cancer? At the 2021 American Endocrine Society Annual Meeting (ENDO), Dr.
Cari Kitahara from the National Cancer Institute (affirmative) and Dr.
Brian Kim from Rush University Medical Center (affirmative) debated this topic.
Zhengfang Dr.
Cari Kitahara believes that ionizing radiation is a known carcinogen, which is related to the increased risk of solid cancer and blood cancer.
Dr.
Kitahara summarized a study published by his team in JAMA Intern Med in 2019 (PMID: 31380945), which investigated a group of patients with hyperthyroidism (18,805) who were treated with RAI, and the study was followed up for 70 years.
This study showed that patients with hyperthyroidism treated with RAI have an increased risk of all solid cancers (especially breast cancer in women), even if the patients received relatively low doses of RAI.
The opponent, Dr.
Brian Kim, believes that despite the extensive heterogeneity in previous studies, there have been more than 100 years of safety data regarding the correlation between RAI treatment and thyroid cancer.
Relevant recommendations based on these evidences can ensure the overall safety of RAI in patients with hyperthyroidism.
Although scholars failed to reach a consistent conclusion on the "relevance of radioactive iodine and cancer risk" in this debate, there are still important revelations: it is important to evaluate the quality of evidence in previous related studies, and recently published studies The data prompts us to conduct more related investigations.
Yimaitong compiled and compiled from: Angela M.
Leung.
Thyroid Highlights From ENDO 2021[EB/OL].
